Literature DB >> 8092849

Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period.

M F Price1, M T LaRocco, L O Gentry.   

Abstract

The distribution and fluconazole susceptibilities of Candida species isolated over a 5-year period were investigated. Susceptibilities were determined by using a new microtiter procedure and the National Committee for Clinical Laboratory Standards (NCCLS) proposed standard. The new method correlated well with the NCCLS proposed standard and gave very clear end points. Results indicate that there are species-related differences in MICs as reflected in the MICs for 90% of species tested. Candida albicans is most susceptible to fluconazole, while Candida glabrata is among the least susceptible. These findings coincided with the observation of a shift in distribution of yeast species recovered from blood cultures from 1987 to 1992. C. albicans was the predominant species (87%) in the pre- or early fluconazole years but decreased to only 31% of the isolates in 1992. Thus, Candida species for which MICs of fluconazole were higher have become more prominent in recent years. Significantly, throughout this period, MICs for each species did not change appreciably.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8092849      PMCID: PMC188224          DOI: 10.1128/AAC.38.6.1422

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  5 in total

1.  Standardized susceptibility testing of fluconazole: an international collaborative study.

Authors:  M A Pfaller; B Dupont; G S Kobayashi; J Müller; M G Rinaldi; A Espinel-Ingroff; S Shadomy; P F Troke; T J Walsh; D W Warnock
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

Review 2.  Progress in standardizing antifungal susceptibility tests.

Authors:  J N Galgiani
Journal:  Clin Lab Med       Date:  1989-06       Impact factor: 1.935

3.  Growth phase in relation to ketoconazole and miconazole susceptibilities of Candida albicans.

Authors:  W H Beggs
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

4.  Fluconazole susceptibility testing of Candida albicans: microtiter method that is independent of inoculum size, temperature, and time of reading.

Authors:  E Anaissie; V Paetznick; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

5.  Collaborative investigation of broth microdilution and semisolid agar dilution for in vitro susceptibility testing of Candida albicans.

Authors:  R Shawar; V Paetznick; Z Witte; L G Ensign; E Anaissie; M LaRocco
Journal:  J Clin Microbiol       Date:  1992-08       Impact factor: 5.948

  5 in total
  65 in total

Review 1.  The ins and outs of DNA fingerprinting the infectious fungi.

Authors:  D R Soll
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

2.  Management of Infections Caused by Candida glabrata.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-10       Impact factor: 3.725

3.  Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group.

Authors:  P Phillips; S Shafran; G Garber; C Rotstein; F Smaill; I Fong; I Salit; M Miller; K Williams; J M Conly; J Singer; S Ioannou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-05       Impact factor: 3.267

4.  Outbreak of Pichia anomala infection in the pediatric service of a tertiary-care center in Northern India.

Authors:  A Chakrabarti; K Singh; A Narang; S Singhi; R Batra; K L Rao; P Ray; S Gopalan; S Das; V Gupta; A K Gupta; S M Bose; M M McNeil
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

5.  Trends in antifungal use and epidemiology of nosocomial yeast infections in a university hospital.

Authors:  Y F Berrouane; L A Herwaldt; M A Pfaller
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

6.  Comparison of the API Candida system with the AUXACOLOR system for identification of common yeast pathogens.

Authors:  C K Campbell; K G Davey; A D Holmes; A Szekely; D W Warnock
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

Review 7.  Fluconazole. An update of its antimicrobial activity, pharmacokinetic properties, and therapeutic use in vaginal candidiasis.

Authors:  C M Perry; R Whittington; D McTavish
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

8.  Detection of fluconazole-resistant isolates of Candida glabrata by using an agar screen assay.

Authors:  Susan M Nelson; Charles P Cartwright
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

9.  Azole resistance in Candida glabrata: coordinate upregulation of multidrug transporters and evidence for a Pdr1-like transcription factor.

Authors:  John-Paul Vermitsky; Thomas D Edlind
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

10.  Hospital specificity, region specificity, and fluconazole resistance of Candida albicans bloodstream isolates.

Authors:  M A Pfaller; S R Lockhart; C Pujol; J A Swails-Wenger; S A Messer; M B Edmond; R N Jones; R P Wenzel; D R Soll
Journal:  J Clin Microbiol       Date:  1998-06       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.